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Abstract
Background: Accurate quantitative detection of hepatitis C virus (HCV) RNA is critical for diagnosis of acute or
chronic HCV infection, and for follow-up of virologic response during HCV targeted therapy. In the present study,
traceability and reproducibility of a novel China-certified domestic Sansure HCV RNA diagnostic assay (Sansure,
Changsha, Hunan, China) was evaluated and the clinical performance of this assay was also analyzed.
Methods: Traceability of the Sansure HCV RNA assay to the WHO international standard for HCV (genotype 1a) was
detected across multiple centers. Reproducibility, accuracy (the differences of observed average concentrations and
expected concentrations) and precision were assessed using series dilutions of World HCV RNA performance panel
WWHV303-02 (HCV-1b), WWHV303-04(HCV-2a), WWHV303-11(HCV-3a) and WWHV303-19 (HCV-6a). In addition, both
Sansure HCV RNA and CAP/CTM HCV (Roche, Branchburg, NJ, USA) assays were used to detect HCV RNA in 346
EDTA anti-coagulated plasma samples from previous HCV-infected patients, during and after antiviral therapy.
Results: The Sansure assay showed good traceability by agreeing with the HCV-1a WHO standard across all five
concentrations tested (25, 50, 100, 1000, 10000 IU/ml). The differences between observed average concentrations
and expected concentrations were all within 0.2 log10 IU/ml. HCV WWHV303 standards across 4 HCV genotypes
(1b, 2a, 3a and 6a) were used for evaluation of reproducibility and the accuracy of the test were all within 0.2 log10
IU/ml. The inter-assay variations across the above 4 HCV genotypes were all less than 0.03 on each evaluated
concentration, indicating good precision of Sansure HCV RNA assay. In clinical practice, concordant results were
determined in 99.42 % (344/346) samples (215 positive and 129 negative samples). Two specimens with negative
HCV RNA results by Sansure assay were detected positive by CAP/CTM HCV test. Correlation analysis indicated a
significantly positive correlation in detected HCV RNA concentrations (r = 0.9439, P < 0.0001). HCV RNA levels in
95.35 % (205/215) specimens were within mean difference ± 1.96 SD as tested by both assays.
Conclusions: With the advantages of traceability, reproducibility and lower price, Sansure HCV RNA assay
represented an alternative option for HCV RNA detection in hospital and medical institution in China.
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Background
Chronic hepatitis C (CHC) and its associated cirrhosis
and hepatocellular carcinoma (HCC) are major chal-
lenges of global public health [1, 2]. According to a
national survey carried out in 2006, the prevalence of
anti-HCV was estimated as 0.43 % in general population
in mainland China [3]. However, considering a much
higher prevalence of anti-HCV in high-risk groups, such
as paid blood donors, patients on hemodialysis, patients
with hemophilia, injection drug users (IDUs), persons
with multiple sex partners and men who have sex with
men and HIV-infected subjects, the “true” prevalence of
anti-HCV was re-estimated to be around 1 % in China
[4]. Thus, the absolute anti-HCV positive population
may reach approximately 13 million at present. The
common HCV genotype in Chinese CHC patients was
genotype 1b, accounting for nearly half of HCV infected
subjects, followed by genotypes 2a, 3a and 6a [5].
In recent years, the emergence of direct-acting antivi-
rals (DAAs) has substantially improved the rate of SVR
(sustained viral response) and thus has brought
profound influence on the landscape of HCV therapy
[6–10]. Therefore, it is essential to quantify HCV RNA
using reliable and sensitive assays to monitor the out-
comes of anti-HCV treatment, either by traditional Peg-
IFNα/ribavirion (RBV) dual scheme or all-oral Peg-
IFNα-free and RBV-free therapy achieved by once-daily
single-tablet DAAs regimens. In addition, identification
of acute HCV infection also depends on sensitive and re-
producible HCV RNA detection, especially for those
with low HCV viral load [11–13]. European association
for the study of the liver (EASL) recommendations on
treatment of hepatitis C 2014 specifically pointed out
that the diagnosis of acute and chronic HCV infection
was based on the detection of HCV RNA by a sensitive
molecular method with detection limit lower than
15 IU/ml, and suggested that the endpoint for therapy
should be determined by higher quality detection kits
with lower limit less than 15 IU/ml [14].
The world Health Organization (WHO) expert com-
mittee has established an international standard for
worldwide HCV RNA (genotype 1a) nucleic acid test.
The standard allows results of quantitative HCV RNA
detection results reporting in IU/ml by facilitating assays
to be compared to an international standard. In China,
in addition to the international HCV RNA quantification
kits, such as Cobas Ampliprep/Cobas Taqman (CAP/
CTM) HCV test kit (Roche) and Abbott Realtime HCV
kit (Abbott), several domestic certified assays have also
been used in clinical practice, especially in primary med-
ical care and hospitals in un-developed regions. How-
ever, the comparability of domestic-certified HCV RNA
assays to international standards is unknown. In this
study, traceability and reproducibility of a novel Sansure
HCV RNA quantitative fluorescence diagnostic assay
(PCR-Fluorescence Probing) (Sansure) were evaluated
across 4 main HCV genotypes in China. Finally, clinical
performance of Sansure HCV assay was evaluated and
compared with CAP/CTM HCV test (version 2) using
plasma samples from chronic HCV-infected patients,
during and after antiviral therapy.
Methods
Sansure HCV RNA assay and Roche CAP/CTM HCV test
Nucleic acid extraction, PCR reaction preparation and
amplification of Sansure HCV RNA detection assay were
performed on Natch S workstation (Natch S system,
Sansure Biotech, Inc, Changsha, Hunan, P.R China)
using protocols, reagents and software provided by the
manufacturer. 0.2 ml serum/plasma samples were proc-
essed automatically. In the Sansure HCV assay, magnetic
bead technology was used to extract HCV-RNA from
human serum or plasma. Real-time fluorescence quanti-
tative PCR technology was applied to quantify HCV
RNA, by using a pair of specific primers, which were de-
signed to target a conserved sequence of HCV-RNA,
and a specific fluorescence probe, accompanied with
other ingredients in PCR-Master mix. A total of 96 sam-
ples (16 samples/batch × 6 batches), including 90 test
samples, quantitative references A-D, positive control
and negative control were tested in one run. The quant
references A-D were composed of inactivated positive
HCV samples with different viral loads to generate lad-
der as reference. PCR inhibitors, including hemoglobin,
bilirubin and triglyceride, have been added into samples
during amplification. Testing results indicated that in-
hibitors had no effect on PCR amplification within the
following concentration: hemoglobin (≤2 g/dl), bilirubin
(≤28 mg/dl), triglyceride (≤3000 mg/dl), total IgG
(≤40 g/l). In addition, positive control (Internal Control),
which was designed to monitor the effect of inhibitors
on PCR amplification, was added into the extraction and
amplification system. Amplification results of diluted
samples proved normal Ct value and no delay of internal
control, confirming that all inhibitors were within the
acceptable range and had no interference in the PCR
system. The Natch S workstation extracted nucleic acids
and assembled PCR reactions in 130 min. The SLAN-96
instrument performed PCR, analyzed the fluorescence
data, and calculated the results in 2 h. The linear range
of Sansure HCV assay is ranged from 50 IU/ml to 1.0E
+ 08 IU/ml and its limit of detection (LOD) is set as
25 IU/ml according to manufacturer’ instruction.
The performance of the 2nd Cobas Ampliprep/Cobas
Taqman (CAP/CTM) HCV Test system (Roche, Branch-
burg, NJ, USA) was strictly followed the instructions
provided by the manufacturer, as described previously
[15]. The LOD of CAP/CTM assay is 15 IU/ml and the
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log difference of LOD between Sansure and CAP/CTM
assays is 0.22 log10 IU/ml.
HCV RNA Standards
The 4th WHO international standard for HCV for nu-
cleic acid amplification technology (NAT)-based assays
(Code 06/102) (genotype 1a) was purchased from the
National Institute for Biological Standards and Control
(NIBSC) [16], which was positive for anti-HCV (detected
by both Abbott Architect anti-HCV assay and Ortho
HCV version 3.0 ELISA test) and HCV RNA (original
concentration: 260000 IU/ml) and was used to assess
traceability of Sansure HCV RNA quantitative assay.
World HCV RNA performance panel WWHV303 [17]
(SeraCare Life Sciences, USA) was used for evaluating
reproducibility of Sansure HCV RNA quantitative assay.
Traceability assessment
In order to determine traceability of Sansure HCV RNA
assay to the WHO international standard, a panel of
HCV RNA standards consisting of five dilutions 25, 50,
100, 1,000 and 10,000 IU/ml was created. The dilution
was performed using HCV-negative human EDTA
plasma (both HCV RNA- negative and anti-HCV nega-
tive) and tested at three different centers, including In-
fectious Disease Center of Peking University Health
Science Center, Nanfang Hospital of Southern Medical
University, and Xiangya Hospital of Central South Uni-
versity. The negative plasmas were tested before use and
were proved without interference on PCR results. For
each assay, three single run per day was performed for 3
consecutive days at each center. The Sansure kits with
three different lots were used in the three study centers.
Reproducibility assessment
The original HCV RNA concentrations of 4 panels includ-
ing WWHV303-02 (HCV-1b), WWHV303-04(HCV-2a),
WWHV303-11(HCV-3a) and WWHV303-19 (HCV-6a)
were detected as 6.3 × 106, 1.3 × 105, 3.7 × 104 and 2.9 ×
105 IU/ml by Roche 2nd CAP/CTM HCV test, respect-
ively. The information of HCV genotypes and diluted
HCV RNA concentration of World HCV RNA perform-
ance panels used in this study were listed in Table 1.
Briefly, HCV-1b plasma (WWHV303-02) was diluted to 6
dilutions 25, 50, 100, 1,000, 10,000 and 100,000 IU/ml,
and HCV-2a (WWHV303-04), HCV-3a (WWHV303-11)
and HCV-6a (WWHV303-19) were diluted to 4 dilutions
25, 50, 100 and 1,000 IU/ml. Reproducibility evaluation of
Sansure HCV RNA detection was performed by testing
each panel in triplicate across the three study centers
mentioned above. The Sansure kits with three different
lots were used in the three study centers.
Comparison between Sansure HCV RNA assay and Roche
CAP/CTM HCV test in clinical samples
The consistency between Sansure HCV RNA quantita-
tive assay and Roche CAP/CTM HCV test was com-
pared using 346 EDTA plasma samples from patients at
least 18 years of age diagnosed as chronic HCV infection
previously. The samples were collected during and after
antiviral therapy with Peg-IFNα/ribavirion (RBV) dual
regimen. All specimens chosen for this study were posi-
tive for anti-HCV response. HCV RNA quantitative de-
tection by CAP/CTM HCV test was performed at
Nanfang hospital and Xiangya Hospital. Sansure HCV
RNA assay was performed at Infectious Disease Center
of Peking University Health Science Center. Of the 346
specimens, HCV viral load was detectable in 217 sam-
ples by CAP/CTM HCV test, ranging from 1.53E +
01 IU/ml to 7.75E + 07 IU/ml, and was undetectable in
129 samples according to CAP/CTM test. Of 217 HCV
RNA positive samples, 147 were detected as genotype
1b, 30 were 2a, 20 were 3a and 20 were 6a.
Statistical Analysis
HCV RNA quantitative results were shown as log10 IU/
ml. Means, standard deviations, the absolute difference
between observed mean values and the expected con-
centrations and coefficients of variation were calculated
by descriptive statistics. Correlation between Sansure
HCV RNA assay and Roche CAP/CTM test was deter-
mined by linear regression analysis. In both traceability
and accuracy analysis, observed concentrations within
±0.3 log10 of the excepted concentration in IU/ml were
considered acceptable [18]. The precision of log10-trans-
formed valid test results (within the range of the assay)
was estimated at each expected log10 HCV RNA concen-
tration for each genotype. The lognormal CV (%) was
calculated by linear mixed effect model with site and
day/run, and within-run as random effects. All statistical
analyses were performed using GraphPad Prism 5.0 soft-
ware (San Diego, CA, USA).
Table 1 Characteristics of 4 World HCV RNA Performance






Taqman HCV test (IU/ml)
Dilutions of panel
member (IU/ml)
WWHV303-02 1b 6.3*106 100000,10000,1000,
100, 50, 25
WWHV303-04 2a 1.3*105 1000, 100, 50, 25
WWHV303-11 3a 3.7*104 1000, 100, 50, 25
WWHV303-19 6a 2.9*105 1000, 100, 50, 25
Huang et al. BMC Infectious Diseases  (2016) 16:47 Page 3 of 8
Ethics review
The study was approved by the institutional review au-
thorities of Peking University Health Science Center
(Approval ID: PKUPHLL20090011). Informed consent
was obtained from each patient. Testing was performed
according to the recommendations from the Clinical
Laboratory Standards Institute (CLSI) guidelines.
Results
Assessment of traceability
Traceability of the Sansure HCV RNA assay was com-
pared with the the 4th HCV WHO international stand-
ard (genotype 1a). As shown in Table 2, the detection
results of Sansure assay were consistent within all five
diluted concentrations (25, 50, 100, 1000, 10000 IU/ml)
of HCV WHO standard and the differences between ob-
served average concentrations and expected concentra-
tions of all dilutions were within 0.2 log10 IU/ml
(concentration range, -0.055 to +0.198 IU/ml). Standard
deviation of the Sansure HCV RNA assay ranged from
0.032 to 0.143 log10 IU/ml in a total of 27 repeated de-
tections with HCV-1a RNA concentrations ranging from
25 to 10000 IU/ml, indicating good precision of the
assay (Table 2).
Assessment of reproducibility, accuracy and precision
Four World HCV RNA Performance Panels were used
for evaluation of the reproducibility of Sansure HCV
RNA assay. As shown in Table 3, the observed results of
Sansure assay were in agreement with the HCV
WWHV303 standards across all four HCV genotypes
(1b, 2a, 3a and 6a) and the accuracy (the differences be-
tween observed average concentrations and expected
concentrations) of all tests was within 0.2 log10 IU/ml.
The biggest difference across the results was -0.114 log10
IU/ml, which occurred in detection of WWHV303-04
(HCV-2a) on the highest concentration of 1000 IU/ml of
expected HCV RNA value. In addition, among different
concentrations in each genotype, the inter-assay vari-
ation of Sansure assay was always less than 0.03 (3 %),
indicating that Sansure assay has a good precision across
four HCV genotypes. Considering genotype 1b is the
most popular HCV subtype prevailing in China and the
original concentration of WWHV303-02 (HCV-1b) is up
to 6.3 × 106 IU/ml, standards for HCV-1b genotype was
diluted to 6 dilutions (25, 50, 100, 1,000, 10,000 and
100,000 IU/ml), while the maximum dilution of other 3
genotypes (HCV-2a, 3a, and 6a) was 1000 IU/ml due to
the original concentrations (Table 1). For evaluation of
HCV-1b, low lognormal coefficient of variation (CV%)
was found in 10000 IU/ml (1.41) and 100000 IU/ml
(0.989) dilutions while high CV% was observed in 25 IU/
ml (10.01), 50 IU/ml (4.023), 100 IU/ml (4.486) and
1000 IU/ml (5.055) dilutions. These results indicated
that better stability of Sansure assay presented in higher
viral load than in lower ones.
Quantification of HCV RNA in clinical practice
In order to determine the clinical evaluation of Sansure
assay, a total of 346 plasma samples from patients with
chronic HCV infection were collected during and after
antiviral therapy. Comparison of HCV RNA levels mea-
sured by Sansure assay and Roche CAP/CTM test was
shown in Table 4. Among the 346 clinical samples, 344
samples were consistently tested by both assays and con-
cordant result was determined in 99.42 % of total sam-
ples. None of the 129 matched HCV-negative samples
determined by CAP/CTM HCV test gave a false-positive
HCV RNA result with Sansure assay, achieving a specifi-
city of 100 %. Only two specimens with negative HCV
RNA results by Sansure assay were detected positive by
CAP/CTM HCV test (HCV-3a for 1.53E + 01 IU/ml and
HCV-6a for 1.82E + 01 IU/ml respectively), which indi-
cated that Sansure assay was slightly less sensitive than
CAP/CTM test, especially in low viral loads samples.
215 samples which were HCV RNA-positive as de-
tected by both Sansure HCV RNA assay and Roche
CAP/CTM HCV assay were further analyzed. As shown
in Fig. 1, the values of HCV RNA concentrations de-
tected by Sansure HCV RNA assay and Roche CAP/
CTM HCV assay were highly correlated (r = 0.9439, P <
0.0001; Fig. 1a). We further analyzed the corrections of
two assays in different HCV genotypes. 215 HCV RNA-
positive samples included 147 genotype 1b, 30 genotype








Difference of Observed and
Expected HCV RNA (log10 IU/ml)
Standard Deviation of the
mean HCV RNA (log10 IU/ml)
25 1.398 1.596 0.198 0.032
50 1.699 1.812 0.113 0.081
100 2 2.173 0.173 0.050
1000 3 2.969 −0.031 0.043
10000 4 3.945 −0.055 0.143
Each test had 27 results with panel members within the range of the assay
a The limit of detection (LOD) of Sansure Realtime HCV assay is 25 IU/ml and its linear range is defined as from 5.0E + 01 IU/ml to 1.0E + 08 IU/ml
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2a, 19 genotype 3a and 19 genotype 6a. The correlations
analysis indicated that Sansure assay were highly cor-
related (P < 0.001 for all) with CAP/CTM test for 1b
(r = 0.9362, Fig. 1b) and 6a (r = 0.9474, Fig. 1c) geno-
types, and to a less degree for 3a (r = 0.8333, Fig. 1d)
and 2a (r = 0.6962, Fig. 1e).
Bland-Altman analysis showed that the mean different
value of the 215 paired viral loads, maximal difference,
and 95 % confidence interval were -0.024, 1.35 and
(−0.844, 0.796) log10 IU/ml, respectively (Fig. 2a). The
largest differences in the HCV RNA values were located
in the range of mean difference ±1.96 SD (95.35 %, 205/
215) and 10 were out of the range of mean difference
±1.96 SD. Since the majority of clinical samples in this
study were genotype 1b, we specially performed Bland-
Altman analysis for 147 1b samples, and the results
indicated that mean different value, maximal difference,
and 95 % confidence interval were 0.004, 1.20 and
(−0.596, 0.605) log10 IU/ml, respectively (Fig. 2b). Only 5
values were out of the range of mean difference ±1.96
SD. These results indicated that the values of HCV RNA
detected by Sansure HCV RNA assay and Roche CAP/
CTM HCV assay in genotype 1b samples were closely
correlated.
Discussion
Hepatitis C virus is one of the major causes of chronic
hepatitis, liver cirrhosis and fibrosis, and hepatocellular
carcinoma. HCV genotyping and viral load at the time
point of diagnosis are used to determine the duration of
antiviral therapy and to predict the response to antiviral
treatment. HCV RNA quantification plays a critical role
in diagnosis of acute HCV infection, evaluating the effi-
cacy of antiviral therapy and prognosis. Although several
commercial HCV RNA quantitative reagents were avail-
able in diagnostic market in China, some quality param-
eters of these reagents, such as linear range, sensitivity,
and precision for low-copy samples, are of great differ-
ences. After antiviral treatment, HCV RNA of some pa-
tients with negative results as detected by some
domestic assays were still detected positive by some
international brand commercial assays, which indicated
Table 3 Total precision (variance, standard deviation and CV %) of PCR assays for HCV genotypes 2b, 1a, 3a and 6a (mean log10














(SD) of log10 HCV RNA
Lognormal
CV%
WWHV303-02 (1b) 25 1.398 9 1.372 −0.026 0.019 (0.137) 10.01
50 1.699 9 1.665 −0.034 0.004 (0.067) 4.023
100 2 9 1.951 −0.049 0.008 (0.088) 4.486
1000 3 9 2.959 −0.041 0.022 (0.150) 5.055
10000 4 9 4.015 0.015 0.003 (0.057) 1.410
100000 5 9 5.049 0.049 0.002 (0.050) 0.989
WWHV303-04 (2a) 25 1.398 9 1.411 0.013 0.012 (0.109) 7.755
50 1.699 9 1.710 0.011 0.009 (0.093) 5.453
100 2 9 2.022 0.022 0.016 (0.126) 6.231
1000 3 9 2.886 −0.114 0.017 (0.130) 4.513
WWHV303-11 (3a) 25 1.398 9 1.379 −0.019 0.013 (0.113) 8.181
50 1.699 9 1.737 0.038 0.007 (0.080) 4.664
100 2 9 2.044 0.044 0.019 (0.139) 6.798
1000 3 9 2.893 −0.107 0.023 (0.150) 5.185
WWHV303-19 (6a) 25 1.398 9 1.413 0.015 0.013 (0.112) 7.958
50 1.699 9 1.712 0.013 0.008 (0.087) 5.100
100 2 9 1.980 −0.02 0.026 (0.162) 8.170
1000 3 9 2.915 −0.085 0.017 (0.130) 4.478
Abbreviations: SD standard deviation
Table 4 Clinical performance of the Sansure HCV RNA assay
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that the sensitivity and repeatability of domestic assays
need to be improved. Due to the high sensitivity, accur-
acy, reproducibility and wide linear range, CAP/CTM
HCV test is recognized as reference for HCV RNA re-
agents internationally. Specially, the 2nd CAP/CTM test
demonstrated good performance and higher sensitivity
with lower limit of quantification of 15 IU/ml across all
HCV genotypes [15]. Unfortunately, the relatively high
cost of CAP/CTM HCV test is an economic burden for
low-income patients. As a result, HCV RNA detection
with low cost and high-through input system is becom-
ing more and more necessary for patients and doctors.
The novel nucleic acid extraction system Natch S can
process 96 samples in one test. The extracted RNA is
compatible with common real-time PCR instruments
with high-sensitive PCR reagents from Sansure biotech.
Inc.. Alternatively, collection tubes can be loaded dir-
ectly in Natch S system instead of transferring sample
from collection tube to S-tube, which will save time and
decrease the risk of contamination.
Fig. 1 a High correlations were observed in measurements of HCV RNA positive samples between Sansure HCV RNA assay and Roche CAP/CTM
HCV assay. Correlations between two assays from HCV RNA positive samples were further analyzed for HCV genotype 1b (b), 2a (c), 3a (d), and 6a
(e) samples. 95 % confidence band (black dashed) of the best-fit line (black solid line) was shown. Quality line was indicated by grey dashed line
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In this study, good traceability was achieved by San-
sure assay, as shown by consistency between observed
average concentrations and expected concentrations of
the standard samples, which were within the acceptable
range (relative deviation < ±0.2 log IU/ml) for all diluted
concentrations of the standards. As for reproducibility,
different concentrations of standards on genotype 1b, 2a,
3a and 6a were tested. Generally, for the genotypes pre-
vailing in China, the differences of observed and
excepted HCV RNA standards were all below 0.2 log
IU/ml and all the values of lognormal CV% were lower
than 15 %, indicating that Sansure assay possessed com-
parable accuracy and precision as CAP/CTM HCV test.
However, this study also suggested that the stability of
Sansure HCV assay needs further improvement for sam-
ples with lower concentrations. When evaluating the
clinical plasma samples, concordant results between
Sansure assay and CAP/CTM HCV test were deter-
mined in 99.42 % of total samples and the specificity
was calculated to be 100 %. In addition, a significant
positive correlation on the concentrations (especially for
genotype 1b) detected by these two assays was observed
in our study. The only discrepancy of the results was
that the concentrations of two samples were failed to be
detected by the Sansure assay, whereas was apparently
detectable with CAP/CTM HCV test. Considering two
specimens with negative HCV RNA results by Sansure
assay were detected positive by CAP/CTM HCV test, we
repeated five tests for each of those two samples using
Sansure assay. Results from three of five times were
positive for both samples. The results indicated that the
accuracy and sensitivity of Sansure assay should be fur-
ther enhanced, especially for detection of lower viral
loads specimens. Less input sample volume used in San-
sure HCV RNA assay (200 μl for Sansure vs. 500 μl for
2nd CAP/CTM) may partially contribute to the incon-
sistent detections of the two low-copy samples.
In short, traceability, accuracy and precision between
measurements of Sansure HCV RNA assay and CAP/
CTM HCV test were comparable in evaluating the 4th
WHO international HCV RNA performance panel and
World HCV RNA performance panel WWHV303 in this
study. However, considering the fact the lower limit of
quantitation was set as 25 IU/ml by the manufacture,
the reliability of Sansure HCV RNA assay need to be
further verified in clinical practice.
Conclusions
In the present study, Sansure HCV RNA assay showed
good traceability and reproducibility with high consistency
and correlation with CAP/CTM HCV test in clinical de-
tection. With the advantages of superior flexibility, trace-
ability, reproducibility and lower price, Sansure HCV
RNA assay represent an alternative option for HCV RNA
detection in hospital and medical institution in China.
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